Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Takeda Pharmaceutical has set its FY 2024 guidance at 2.770-2.770 EPS.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Takeda Pharmaceutical Stock Performance
TAK stock opened at $13.86 on Thursday. The firm has a 50-day simple moving average of $14.61 and a two-hundred day simple moving average of $13.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. Takeda Pharmaceutical has a one year low of $12.57 and a one year high of $15.08. The firm has a market cap of $43.86 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 0.27 and a beta of 0.54.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Do ETFs Pay Dividends? What You Need to Know
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.